Movement Alert|Teva Pharmaceutical Falls 3.06% in Regular Trading, Profit-Taking Emerges After Igalmi At-Home Use Approval

Market Focus11-17 02:47

On November 17, Teva Pharmaceutical fell 3.06% in Regular Trading, trading at $43.15 per share, with turnover of $168 million.

The latest catalyst was an FDA approval granted to Teva's US affiliate for at-home use of Igalmi sublingual film to treat agitation associated with mental disorders, expanding the product's use setting.

Teva had completed the BXCL501 asset acquisition in late October for $57.5 million upfront plus up to $67.5 million in contingent payments. The approval strengthens the company's CNS pipeline and follows a strong third quarter in which non-GAAP EPS reached $0.86 and combined revenue from AUSTEDO, AJOVY and UZEDY rose 33% year over year to about $1.1 billion, alongside raised full-year guidance. Despite the positive development, the share decline suggests investors were locking in gains after the recent rally tied to stronger innovation-drug momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment